Aromatase inhibitors in adjuvant therapy of breast cancer: Before, instead of, or beyond tamoxifen

Journal of Clinical Oncology

Volumn 23, Issue 22, 2005, Pages 4850-4852

  Pritchard, Kathleen I ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; EDITORIAL; ENDOMETRIUM CANCER; FOLLOW UP; FRACTURE; HORMONAL THERAPY; HUMAN; LONG TERM CARE; LUNG EMBOLISM; MONOTHERAPY; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; STROKE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; NOTE; SURVIVAL;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 24644503672     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.904     Document Type: Editorial

References (19)

1. Boccardo F, Rubagotti A, Puntoni M, et al: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23:5138-5147, 2005
2. The Arimidex, Tamoxifen Alone or in Combination Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 359:2131-2139, 2002
3. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1091, 2004
4. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC trial efficacy and safety update analysis. Cancer 98:1802-1810, 2003
5. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
6. Fisher B, Redmond C, Brown A, et al: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial 34. J Clin Oncol 4:459-471, 1986
7. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
8. Stewart HJ, Forrest AP, Everington D, et al: Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer: The Scottish Cancer Trials Breast Group 299. Br J Cancer 74:297-299, 1996
9. Stewart DJ, Prescott RJ, Forrest PM: Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years. J Natl Cancer Inst 93:456-462, 2001
10. Fisher B, Dignam J, Bryant AJS, et al: Five versus more than five years of tamoxifen for lymph node negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14. J Natl Cancer Inst 93:684-690, 2001
11. Tormey DC, Gray R, Falkson HC: Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer: Eastern Cooperative Oncology Group. J Natl Cancer Inst 88:1828-1833, 1996
12. Earl H, Gray R, Kerr D, et al: The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: Randomize into aTTom. Clin Oncol (R Coll Radiol) 9:141-143, 1997
13. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996
14. Goss PE, Ingle JN, Martino S, et al: Updated analysis of the NCIC CTG Ma. 17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 22:88s, 2004 (suppl, abstr 3641)
15. Thurlimann BJ, Keshaviah A, Mouridson H, et al: BIG 1-98: Randomized double-blind phase III study to evauate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for post-menopausal women with receptor-positive breast cancer. Proc Am Soc Clin Oncol 23:16s, 2005 (abstr 511; suppl)
16. Thurlimann BJ: The Breast. Presented at the Primary Therapy in Early Breast Cancer Conference, St Gallen, Switzerland, January 26-29, 2005 (abstr S4)
17. Howell A: Completed treatment analysis: Anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. Breast Cancer Res Treat 88:57, 2004 (abstr 1)
18. Coombes RC, Hall E, Snowdon CF, et al: The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-Updated survival analysis. Breast Cancer Res Treat 88:57, 2004 (abstr 3)
19. Jakesz R, Kaufmann M, Gnant M, et al: Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after two years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 88:57, 2004 (abstr 2)